Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis

被引:51
作者
Curtis, Jeffrey R. [1 ]
Lanas, Angel [2 ]
John, Ani [3 ]
Johnson, David A. [4 ]
Schulman, Kathy L. [5 ]
机构
[1] Univ Alabama Birmingham, UAB Ctr Educ & Res Therapeut, Birmingham, AL 35294 USA
[2] Univ Zaragoza, Zaragoza, Spain
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
[5] Outcomes Res Solut Inc, Bolton, MA USA
基金
美国医疗保健研究与质量局;
关键词
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; DIVERTICULAR-DISEASE; CONTROLLED-TRIAL; OSTEOARTHRITIS; COMPLICATIONS; POPULATION; DICLOFENAC; CELECOXIB; EVENTS; TIME;
D O I
10.1002/acr.21764
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To estimate the incidence and risk factors for gastrointestinal (GI) perforation among patients with rheumatoid arthritis (RA). Methods Claims from employer health insurance plans were used to identify RA patients and those hospitalized for upper or lower GI perforation. GI perforation cases were identified using both a sensitive and a specific definition. A Cox model using fixed and time-varying covariates was used to evaluate the risk of GI perforation. Results Among 143,433 RA patients, and using a maximally sensitive GI perforation definition, 696 hospitalizations with perforation were identified. The rate of perforation was 1.70 per 1,000 person years (PYs; 95% confidence interval [95% CI] 1.581.83), and most perforations (83%) occurred in the lower GI tract. The rate of perforation was lower when a more specific GI perforation definition was used (0.87; 95% CI 0.780.96 per 1,000 PYs). Age and diverticulitis were among the strongest risk factors for perforation (diverticulitis hazard ratio [HR] 14.5 [95% CI 11.817.7] for the more sensitive definition, HR 3.9 [95% CI 2.55.9] for the more specific definition). Among various RA medication groups and compared to methotrexate, the risk of GI perforation was highest among patients with exposure to nonsteroidal antiinflammatory drugs (NSAIDs), concomitant nonbiologic disease-modifying antirheumatic drugs, and glucocorticoids. Biologic agents without glucocorticoid exposure were not a risk factor for perforation. Conclusion GI perforation is a rare but serious condition that affects patients with RA, most frequently in the lower GI tract. Clinicians should be aware of risk factors for GI perforation when managing RA patients, including age, history of diverticulitis, and use of glucocorticoids or NSAIDs.
引用
收藏
页码:1819 / 1828
页数:10
相关论文
共 22 条
[1]   Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs [J].
Briesacher, B ;
Kamal-Bahl, S ;
Hochberg, M ;
Orwig, D ;
Kahler, KH .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (15) :1679-1684
[2]  
Cafardi JM, 2008, HANDB SYST AUTOIMMUN, V8, P109, DOI 10.1016/S1571-5078(07)00010-4
[3]   Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial [J].
Chan, Francis K. L. ;
Lanas, Angel ;
Scheiman, James ;
Berger, Manuela F. ;
Nguyen, Ha ;
Goldstein, Jay L. .
LANCET, 2010, 376 (9736) :173-179
[4]   A Novel Composite Endpoint to Evaluate the Gastrointestinal (GI) Effects of Nonsteroidal Antiinflammatory Drugs Through the Entire GI Tract [J].
Chan, Francis K. L. ;
Cryer, Byron ;
Goldstein, Jay L. ;
Lanas, Angel ;
Peura, David A. ;
Scheiman, James M. ;
Simon, Lee S. ;
Singh, Gurkirpal ;
Stillman, Martin J. ;
Wilcox, Charles M. ;
Berger, Manuela F. ;
Breazna, Aurora ;
Dodge, William .
JOURNAL OF RHEUMATOLOGY, 2010, 37 (01) :167-174
[5]   Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients [J].
Curtis, Jeffrey R. ;
Chen, Shih-Yin ;
Werther, Winifred ;
John, Ani ;
Johnson, David A. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (11) :1150-1158
[6]   The Incidence of Gastrointestinal Perforations Among Rheumatoid Arthritis Patients [J].
Curtis, Jeffrey R. ;
Xie, Fenglong ;
Chen, Lang ;
Spettell, Claire ;
McMahan, Raechele M. ;
Fernandes, Joaquim ;
Delzell, Elizabeth .
ARTHRITIS AND RHEUMATISM, 2011, 63 (02) :346-351
[7]  
Goh H, 2002, ANN ROY COLL SURG, V84, P93
[8]  
Gu NY, 2010, AM J PHARM BENEFIST, V2, P351
[9]   Concurrent drug use and the risk of perforated colonic diverticular disease: a population-based case-control study [J].
Humes, David J. ;
Fleming, Kate M. ;
Spiller, Robin C. ;
West, Joe .
GUT, 2011, 60 (02) :219-224
[10]   Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison [J].
Laine, Loren ;
Curtis, Sean P. ;
Cryer, Byron ;
Kaur, Amarjot ;
Cannon, Christopher P. .
LANCET, 2007, 369 (9560) :465-473